YourEncore Program to Help Pharmaceutical Companies Make Phase III Trial Decisions

YourEncore announced that it is launching a program that will help pharmaceutical companies decide if they should go forward with phase III trials.

As quoted in the press release:

YourEncore hand-selects teams of leading clinical, regulatory, commercial and market access experts for each project based on disease and therapeutic areas of expertise. After a rigorous study of the data, the team assesses the likelihood of success in Phase III and may recommend changes in protocol design, labeling and claims to increase the odds of approval.

Lisa M. Arbogast, vice president of Life Sciences at YourEncore, commented:

The stakes couldn’t be higher, yet nearly four in 10 drugs in Phase III fail to get approval. Our Independent Challenge Teams (ICTs) provide an unbiased expert perspective that can help a company avoid failures during this critical stage of testing.

Click here to read the full YourEncore press release.